Dimethyl 2-(2-hydroxyethyl)heptanedioate | 1160961-04-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Dimethyl 2-(2-hydroxyethyl)heptanedioate
• 英文别名: dimethyl 2-(2-hydroxyethyl)heptanedioate
• CAS: 1160961-04-5
• 化学式: C₁₁H₂₀O₅
• 分子量: 232.277
• InChiKey: VUNVROQEQTYGRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[(18S,25S,35S)-35-[(S)-hydroxy(phenyl)methyl]-28-(methoxymethyl)-21-methyl-18-[2-(methylamino)-2-oxoethyl]-16,23,30,33-tetraoxo-25-propan-2-yl-3,13,20,27,37-pentathia-7,17,24,31,34,39,40,41,42,43-decazaheptacyclo[34.2.1.12,5.112,15.119,22.126,29.06,11]tritetraconta-1(38),2(43),4,6(11),7,9,12(42),14,19(41),21,26(40),28,36(39)-tridecaen-8-yl]-1,3-thiazole-4-carbonyl azide 、 Dimethyl 2-(2-hydroxyethyl)heptanedioate 以 甲苯 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  Discovery of LFF571: An Investigational Agent for Clostridium difficile Infection

  摘要：

  Clostridium difficile (C. difficile) is a Gram positive, anaerobic bacterium that infects the lumen of the large intestine and produces toxins. This results in a range of syndromes from mild diarrhea to severe toxic megacolon and death. Alarmingly, the prevalence and severity of C. difficile infection are increasing; thus, associated morbidity and mortality rates are rising. 4-Aminothiazolyl analogues of the antibiotic natural product GE2270 A (1) were designed, synthesized, and optimized for the treatment of C. difficile infection. The medicinal chemistry effort focused on enhancing aqueous solubility relative to that of the natural product and previous development candidates (2, 3) and improving antibacterial activity. Structure-activity relationships, cocrystallographic interactions, pharmacokinetics, and efficacy in animal models of infection were characterized. These studies identified a series of dicarboxylic acid derivatives, which enhanced solubility/efficacy profile by several orders of magnitude compared to previously studied compounds and led to the selection of LFF571 (4) as an investigational new drug for treating C. difficile infection.

  DOI：

  10.1021/jm201685h
• 作为产物：
  描述：

  4-carbomethoxy-6-t-butyldimethylsiloxy-1-hexene 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 palladium on activated charcoal 、 camphor-10-sulfonic acid 、 氢气 作用下， 以 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 1.0h， 生成 Dimethyl 2-(2-hydroxyethyl)heptanedioate
  参考文献：
  名称：

  Discovery of LFF571: An Investigational Agent for Clostridium difficile Infection

  摘要：

  Clostridium difficile (C. difficile) is a Gram positive, anaerobic bacterium that infects the lumen of the large intestine and produces toxins. This results in a range of syndromes from mild diarrhea to severe toxic megacolon and death. Alarmingly, the prevalence and severity of C. difficile infection are increasing; thus, associated morbidity and mortality rates are rising. 4-Aminothiazolyl analogues of the antibiotic natural product GE2270 A (1) were designed, synthesized, and optimized for the treatment of C. difficile infection. The medicinal chemistry effort focused on enhancing aqueous solubility relative to that of the natural product and previous development candidates (2, 3) and improving antibacterial activity. Structure-activity relationships, cocrystallographic interactions, pharmacokinetics, and efficacy in animal models of infection were characterized. These studies identified a series of dicarboxylic acid derivatives, which enhanced solubility/efficacy profile by several orders of magnitude compared to previously studied compounds and led to the selection of LFF571 (4) as an investigational new drug for treating C. difficile infection.

  DOI：

  10.1021/jm201685h

文献信息

• [EN] AMINOTHIAZOLES AND THEIR USES<br/>[FR] AMINOTHIAZOLES ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2009074605A1

  公开（公告）日：2009-06-18

  The present application describes organic compounds that are useful for the treatment, prevention, and/or amelioration of diseases particularly bacterial infections, formula (I), and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, atropisomers or racemates thereof, including the pyridine N-oxide thereof;

  本申请描述了有机化合物，该化合物对治疗、预防和/或缓解疾病特别是细菌感染很有用，该化合物的化学式为(I)，以及其药学上可接受的盐、对映体、立体异构体、转轮异构体、互变异构体、非对映异构体、环异构体或混合物，包括其吡啶N-氧化物。
• AMINIOTHIAZOLES AND THEIR USES
  申请人：Bushell Simon

  公开号：US20130231275A1

  公开（公告）日：2013-09-05

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases particularly bacterial infections.

  本申请描述了有机化合物，可用于治疗、预防和/或改善疾病，特别是细菌感染。
• US20140274878A1
  申请人：——

  公开号：US20140274878A1

  公开（公告）日：2014-09-18
• AMINOTHIAZOLES AND THEIR USES
  申请人：Bushell Simon

  公开号：US20170015704A1

  公开（公告）日：2017-01-19

  The present application describes organic compounds of Formula (I) and pharmaceutical compositions thereof, and their use for the treatment, prevention and/or amelioration of diseases, particularly bacterial infections.
• US9492496B2
  申请人：——

  公开号：US9492496B2

  公开（公告）日：2016-11-15